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Abstract
Background: Turning gene expression on and off at will is one of the most powerful tools for the study of gene
function in vivo. While several conditional systems were successful in invertebrates, in mice the Cre/loxP
recombination system and the tet-controlled transcription activation system are predominant. Both expression
systems allow for spatial and temporal control of gene activities, and, in the case of tet regulation, even for the
reversible activation/inactivation of gene expression. Although the rat is the principal experimental model in
biomedical research, in particular in studies of neuroscience, conditional rat transgenic systems are exceptionally
rare in this species.
Results: We addressed this lack of technology, and established and thoroughly characterized CreERT2 and tTA
transgenic rats with forebrain-specific transgene expression, controlled by the CaMKII alpha promoter. In addition,
we developed new universal rat reporter lines for both transcription control systems and established inducible and
efficient reporter gene expression in forebrain neurons.
Conclusions: We demonstrate that conditional genetic manipulations in the rat brain are both feasible and
practicable and outline advantages and limitations of the Tet and Cre/loxP system in the rat brain.
Keywords: CaMKIIα, conditional expression, Cre/loxP, rat model, Tet system, transgenic rat, tTA
Background
The genetic manipulation of target genes in transgenic
animals in vivo is one of the most valuable tools for asses-
sing gene functions and for modelling human diseases.
The most popular approaches for the generation of geneti-
cally modified mice are the targeted engineering of geno-
mic DNA in embryonic stem cells to introduce gene
knockouts and the DNA microinjection into the pronuclei
of fertilized eggs, which results in random integration of
the transgene into the genome for the overexpression of
gene products.
These valuable techniques have inherent limitations
related to the irreversibility and ubiquity of the germ line
genetic modifications. If essential genes are targeted, this
will potentially lead to embryonic lethality or activation of
compensatory mechanisms, which complicates or even
impedes the phenotypic analyses of these animal models
[1]. In particular this holds true for the large number of
genes involved in the formation of neuronal structures
emerging late in embryonic development or at early
postnatal stages. To overcome these limitations, several
techniques for the spatial and temporal control of gene
expression in genetically modified mice have been pro-
posed and developed [2], of which the Cre/loxP recombi-
nation system [3] and the tet-controlled transcription
activation system (Tet system [4]) have become the most
widely applied and characterized [1].
Cre is a site-specific recombinase that catalyses recombi-
nation between its recognition sites, loxP, leading to an
inversion or deletion of a loxP-flanked DNA sequence.
Hence, Cre recombinase can be applied to delete genes or
to activate transcription by removing a transcriptional ter-
mination (STOP) sequence [1]. To obtain an inducible ver-
sion of Cre, the recombinase was fused to a mutant form
of the human oestrogen receptor, leading to cytoplasmic
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localization and therefore inactivation of the fusion protein
(CreERT2) [5]. Once the ligand tamoxifen is applied,
CreERT2 translocates into the nucleus, where recombina-
tion takes place.
The Tet system is based on two central elements, the
tetracycline (tet)-controlled transactivator (tTA) and a spe-
cific responsive promoter (Ptet), which controls expression
of the transgene [4]. Ptet is specifically activated by bind-
ing of tTA. Tet and tet derivatives such as doxycycline
hydrochloride (Dox) interfere with the DNA-binding
activity of tTA, thereby abolishing transcriptional activa-
tion of Ptet. By tissue-specific expression of Cre recombi-
nase or tTA, the impact of transgenic perturbation can be
limited to defined cell populations.
For many scientific questions the rat is the preferential
animal model [6]. This is mainly related to its larger body
size, relevance to human physiology and large body of
experimental experience with these animals [7]. Rats are of
particular importance in neuroscience because they are the
preferred species for behavioural testing of higher cogni-
tive functions, multielectrode recordings, studies of neuro-
nal regeneration [8] and for gene therapy experiments [9].
Up to now, the establishment of techniques for the
conditional manipulation of genes in the rat is far
behind those for mice [10]. Furthermore, in light of the
recent technological breakthroughs that allow targeted
genomic manipulations in rats, including the application
of zinc finger or transcription activator-like effector
nucleases [11-13] and the development of germ line-
competent rat embryonic stem cells [14,15], there is an
urgent need to introduce conditional technologies for
rats and to develop specific Cre driver lines to realize
tissue-specific genetic modifications.
In this report, we describe the generation of transgenic
rat lines expressing tTA and the tamoxifen-inducible Cre
recombinase CreERT2 under the control of the forebrain-
specific Ca2+/calmodulin-dependent protein kinase IIa
(CaMKIIa) promoter. For functional characterization of
the CaMKIIa-tTA and CaMKIIa-CreERT2 lines, we gen-
erated novel tTA and Cre reporter lines that allow faithful
monitoring of spatial and temporal Ptet-controlled and
Cre/loxP-mediated gene regulation. These novel tTA and
CreERT2 lines can be used for inducible transgene overex-
pression, as exemplified herein with reporter genes, or for
inducible gene knockouts once loxP-flanked gene alleles
become available for the rat genome.
Results and discussion
Inducible gene expression in rats using the Tet system
To establish the tet-controlled conditional gene expres-
sion system in transgenic rats (Figure 1A), we generated
two separate Sprague-Dawley (SD) rat strains either car-
rying the tTA expression unit (referred to as driver line)
or the gene of interest under control of the tet-inducible
promoter Ptet (referred to as response line). Double
transgenic rats were generated by breeding the response
lines with driver lines, generating animals heterozygous
for both transgenic alleles. Such animals will express the
transgene depending on administration of the tet deriva-
tive Dox, which can be supplied in the drinking water.
Generation of CaMKIIa-tTA rat lines
In mice, an 8.5 kb CaMKIIa 5’ regulatory sequence has
been shown to efficiently drive transgenic tTA expression
in excitatory forebrain neurons [16]. The resulting mouse
line (Tg(Camk2a-tTA)1Mmay) is one of the most fre-
quently used transactivator mouse lines generated so far
and its application has been a seminal contribution to the
field of learning and memory [17]. A similar transgenic rat
line would enable and facilitate the study of more complex
cognitive tasks. As a similar well-characterized rat promo-
ter fragment was not available and the cross-species use of
promoters to express tet controlled transactivators
between rats and mice has been successful in the past
[18-20], we decided to use the functionally proven mouse
CaMKIIa promoter to spatially control tTA expression in
transgenic rats (Figure 1A). After DNA microinjection,
nine transgenic CaMKIIa-tTA founders could be identi-
fied, three of which transmitted the transgene to the F1
generation (lines 4.5, 4.7 and 5.1).
Generation of Ptet-controlled rat reporter lines
For functional characterization of CaMKIIa-tTA driver
lines, we generated response lines carrying the reporter
genes luciferase (luc) and enhanced green fluorescent
protein (EGFP) under the control of the bidirectional
tet-inducible promoter (Ptetbi, [21]) (EGFP-Ptetbi-luc
line; Figure 1A). The experimental strategy for creating
the EGFP-Ptetbi-luc lines has previously been described
[22]. In brief, a 75 kb genomic mouse fragment contain-
ing the Ptetbi-controlled transcription unit was used for
microinjection into fertilized SD rat oocytes. In mice,
these genomic sequences have been shown to minimize
the influence of the genomic integration site on tet-
regulated promoters [22,23]. Two transgenic founders
harbouring the full-length transgene could be identified.
Both lines showed broad range Dox-dependent Ptet-
controlled regulation of luciferase in primary fibroblast
cultures after transfection with tTA-encoding plasmids
(data not shown). Therefore, both lines were used to
establish independent reporter lines (EGFP-Ptetbi-luc
66.1 and 71.1).
Analysis of tet-regulated gene expression in double
transgenic CaMKIIa-tTA/EGFP-Ptetbi-luc rats
All three transgenic CaMKIIa-tTA driver lines were
crossed to the response lines to generate double trans-
genic CaMKIIa-tTA/EGFP-Ptetbi-luc rats. In these rats,
preliminary luciferase luminescence analysis of crude
forebrain lysates demonstrated functional Ptet-con-
trolled luciferase expression in two CaMKIIa-tTA driver
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lines (lines 4.5 and 4.7). These were further used for in-
depth analysis of Ptet-controlled gene expression.
Transgenic animals of both tTA driver lines were mated
with both EGFP-Ptetbi-luc response lines (66.1 and 71.1)
to yield double transgenic CaMKIIa-tTA/EGFP-Ptetbi-luc
offspring of all four combinations. Individual animals were
first studied by non-invasive luciferase imaging [24] to
investigate the overall distribution of Ptet-controlled
reporter gene expression (Figure 2A). For that purpose,
rats were injected intraperitoneally with the luciferase
substrate D-luciferin and luciferase activity was monitored
noninvasively in anesthetized animals using a photon
imaging system [25]. As expected, brain-specific luciferase
bioluminescence could be detected only over the head
region of CaMKIIa-tTA/EGFP-Ptetbi-luc rats. The
observed brain-specific transgenic expression was further
confirmed by luciferase measurements in tissue lysates of
liver, kidney, heart, lung, spleen and muscle where the
enzyme activity did not exceed 1 relative light units
(RLU)/μg (data not shown).
To investigate the spatial and quantitative expression
pattern in the brain, we prepared tissue lysates of the
olfactory bulb, cortex, hippocampus and cerebellum
from double transgenic and single transgenic animals
and measured luciferase activity (Figure 2B,C). All four
strain combinations showed comparably high expression
levels in forebrain regions while single transgenic repor-
ter rats of line 66.1 or 71.1 showed practically no luci-
ferase activity, confirming that Ptet-controlled luciferase
expression is dependent on tTA-mediated promoter
activation.
According to the endogenous CaMKIIa expression
pattern, high luciferase activity was found in forebrain
regions, that is, in the olfactory bulb, hippocampus and
cortex, whereas very low enzyme activity was found in
the cerebellum. When luciferase reporter expression was
analysed for both reporters (Figure 2B,C), CaMKIIa-tTA
line 4.5 showed better expression levels in the olfactory
bulb compared with line 4.7 (66.1: P ≤ 0.01; 71.1: P ≤
0.05), whereas luciferase activity in the other regions
was comparable. No statistically significant differences
were found between the two EGFP-Ptetbi-luc lines used,
confirming that both rat lines show equal efficacy in
reporting Ptet-controlled gene activation. However, the
mean of luciferase expression was slightly higher in the
cortex and hippocampus of combination 4.5. × 66.1
compared with all other combinations (Figure 2B,C).
As a consequence, we decided to further investigate
Figure 1 Conditional expression systems in the rat brain. (A) Tet regulatory system. Schematic outline of the constructs used to generate
the transgenic rat lines CaMKIIa-tTA and EGF-Ptetbi-luc rats. The CaMKIIa promoter fragment is used to drive expression of the transcriptional
activator tTA, which binds in the absence of doxycycline (Dox) - but not in its presence - to the tetO containing bidirectional minimal promoter
Ptetbi. tTA binding activates Ptetbi and leads to the simultaneous expression of the reporter genes EGFP and luciferase (luc). (B) CreERT2
inducible gene expression system. Schematic outline of the transcription units incorporated in the CaMKIIa-CreERT2 and CAG.loxP.EGFP rat lines.
In double transgenic CaMKIIa-CreERT2/CAG.loxP.EGFP rats, the CaMKIIa promoter fragment controls expression of the tamoxifen-inducible Cre
recombinase CreERT2. The Cre reporter transgene is based on a CAG promoter controlled transcriptional unit, in which the lacZ gene (nlacZ,
with nuclear localization signal) serves as a STOP fragment to prevent transcription of the posterior gene EGFP. In the non-recombined
configuration, lacZ is broadly expressed but replaced by EGFP when Cre-mediated recombination deletes the loxP-flanked STOP fragment. Dox:
doxycycline hydrochloride; EGFP: enhanced green fluorescent protein; luc: luciferase; tTA: tetracycline-controlled transactivator.
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Figure 2 Luciferase expression in double transgenic CaMKIIa-tTA/EGFP-Ptetbi-luc rats. (A) In vivo imaging of luciferase gene activity.
Representative example of brain bioluminescence after injection of the luciferase substrate D-luciferin. The rats were anaesthetized during the
imaging process using 2.5% isoflurane. Shortly before the measurement, the fur was shaved on top of the head to facilitate the external
detection of internally generated photons. Luciferase bioluminescence was restricted to the head region, which demonstrates brain-specific
expression in CaMKIIa-tTA/EGFP-Ptetbi-luc rats. Photons were scattered by the skull. (B,C) Quantification of luciferase activity in different brain
regions. Animals of the CaMKIIa-tTA lines 4.5 and 4.7 were crossed to the reporter lines EGFP-Ptetbi-luc 66.1 (B) and 71.1 (C), respectively, to
obtain double transgenic animals of all four combinations. Luciferase activity in lysates of double transgenic and single transgenic rats (line 66.1
and 71.1) is reported as relative light units (RLU) per μg protein and presented on a log scale. Luciferase activity conveyed by both CaMKIIa-tTA
lines 4.5 and 4.7 in combination with the Ptet-reporter 66.1 (B) was significantly higher (P < 0.001 for all measured brain regions) than single
transgenic reporter activity (olfactory bulb: F (2,15) = 304, P ≤ 0.001; cortex: F (2,14) = 118, P ≤ 0.001; hippocampus: F (2,14) = 184, P ≤ 0.001;
cerebellum: F (2,14) = 37.3, P ≤ 0.001). Identical highly significant results (P < 0.001 for all subregions versus single transgenic reporter rats of line
71.1) were also found for both tTA driver lines in combination with line EGFP-Ptetbi-luc 71.1 (olfactory bulb: F (2,17) = 174, P ≤ 0.001; cortex: F
(2,17) = 155, P ≤ 0.001; hippocampus: F (2,16) = 205, P ≤ 0.001; cerebellum: F (2,16) = 28.3, P ≤ 0.001) (C). When the luciferase activity mediated
by the two transgenic tTA driver lines was compared between the two, line 4.5 showed a significantly stronger luciferase activity in the olfactory
bulb (dF = 12, P ≤ 0.01 in combination with reporter 66.1 in (B); dF = 13, P ≤ 0.05 with reporter 71.1 in (C)), whereas no significant differences
were found in the other brain regions (B,C). Moreover, luciferase activity of Ptet-reporter lines 66.1 and 71.1 with both tTA driver lines (4.5/66.1
versus 4.5/77.1 and 4.7/66.1 versus 4.7/71.1) was not significantly different (B,C). All data are presented as mean values + standard error of the
mean. Logarithmic data transformation was performed prior to statistical analysis. Stars represent P-values obtained by one-way analysis of
variance followed by Bonferroni post hoc test: ***P < 0.001. RLU: relative light units; tTA: tetracycline-controlled transactivator
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Ptet-controlled gene expression using double transgenic
animals of strain combination 4.5. × 66.1.
Ptet-controlled gene expression in CaMKIIa-tTA/
EGFP-Ptetbi-luc rats was further examined on brain slices,
taking advantage of the second Ptet-controlled reporter
gene EGFP. EGFP was either detected by immunohisto-
chemistry (IHC) using a GFP antibody (Figure 3A-F,H,I)
or directly by fluorescent microscopy (Figure 3J). EGFP
expression was restricted to the forebrain, with strong
EGFP-positive cells in the olfactory bulb (glomerular
layer), the cortical somatomotor and visual areas and
the hippocampal CA1 to CA3 region (pyramidal layer) (Fig-
ure 3A-C). Dual-label fluorescence IHC detecting EGFP
and the neuronal marker NeuN confirmed neuronal cell
specificity of mosaic EGFP expression in CaMKIIa-tTA/
EGFP-Ptetbi-luc rats (Figure 3G-I). Ptet-mediated gene
expression was most prominent in the hippocampus, with
EGFP expression in 58.9% (±8.9%, n = 4) of NeuN-positive
cells in the pyramidal layer of the CA1 region; 42.8%
(±6.5%, n = 3) GFP-positive/NeuN-positive cells in the
CA3; and 46.2% (±5.9%, n = 4) in the hilus of the dentate
gyrus. In the cortex, EGFP expression was highly variable.
However, in regions with notable reporter gene expression,
such as the somatomotor area (layer 5), up to 38.4%
(±6.9%, n = 4) of NeuN cells stained positive for GFP.
The possibility to directly visualize EGFP-expressing
cells indicates a very strong expression using the Tet
system in these transgenic rats (Figure 3J). Luciferase and
EGFP are expressed in the same brain areas, which con-
firms the feasibility of co-expressing two genes at the same
time in rats using the bidirectional tet-promoter Ptetbi
[21]. For the most part, the expression pattern found in
CaMKIIa-tTA rats mirrors the spatial expression pattern
found in CaMKIIa-tTA transgenic mice harbouring a
similar CaMKIIa-tTA construct (olfactory bulb, cortex,
striatum and hippocampus) [16,26,27]. However, only
scarce expression was found in the dentate gyrus of the
hippocampus and in the striatum, and expression in the
cortex was highly mosaic. Endogenous CaMKIIa immu-
noreactivity is detected in most, if not all, neurons in the
forebrain, but not in glial cells [12]. The mouse CaMKIIa
promoter might therefore not have the full expression
range in transgenic rats. However, for transgenic mice, it
has been repeatedly shown that different Ptet transgenes
yield varying patterns of expression in combination with
the same CaMKIIa-tTA transgene [16,27,28] and these
differences are considered to result from integration site-
dependent effects on the expression of the Ptet promoter
[29,30]. We believe that similar mechanisms in the rat
genome could act on the CaMKIIa-tTA transgene as well,
leading to the mosaic-like expression pattern.
Doxycycline-mediated control of gene expression
Next, we assessed whether Ptet-controlled gene expression
could be suppressed with Dox. To that end, we analysed
adult double transgenic CaMKIIa-tTA/EGFP-Ptetbi-luc
rats which had chronically received Dox (+Dox) during
embryonic and postnatal development until postnatal day
(P) 60 (1 mg/mL). IHC for EGFP (Figure 3D-F) demon-
strated that Ptet-controlled reporter gene expression could
be completely suppressed with Dox. These results were
confirmed by luciferase measurements in brain extracts of
the aforementioned brain regions (Figure 3K). In addition,
we show that luciferase activity in adult CaMKIIa-tTA/
EGFP-Ptetbi-luc rats, which previously had not received
Dox, could be efficiently suppressed by Dox treatment
(+Dox adult) when given only during a short period dur-
ing adulthood (P90 to P110) (Figure 3L). Dox treatment
led to a 1000-fold reduction in luciferase expression
in all forebrain-specific regions when compared with
untreated animals (-Dox). These findings confirm that
Ptet-controlled gene expression can be suppressed at any
time during the rat’s life.
If expression of the gene of interest is thought to be det-
rimental during development or if adaptive changes during
development caused by the transgenic overexpression
should be avoided, gene expression should be induced
only after embryonic development. Hence, we determined
whether Ptet-controlled gene expression could be acti-
vated when it was previously shut off with Dox (±Dox) for
a period of continuous suppression during development.
Dox was permanently administered to double transgenic
rats during development (10 μg/mL) either until embryo-
nic day (E) 18, P0 or P10, after which Dox was removed
from the drinking water. Brain tissue was prepared from
double transgenic offspring at P60 for luciferase quantifi-
cation and IHC analyses (Figure 4). Interestingly, we
found an inverse correlation between the length of Dox
treatment during development and the efficiency of Ptet-
controlled reporter gene expression after Dox withdrawal.
Rats treated with Dox until E18 were found to exhibit
superior induction of reporter gene activity compared with
rats that were treated until P0 or P10 (Figure 4A). How-
ever, even in rats treated with Dox until E18 only, the
expression level did not fully reach the activation level of
untreated animals (-Dox, Figure 4A). GFP antibody stain-
ing of rats treated with Dox until E18 revealed inducible
gene expression mainly in the olfactory bulb (glomerular
layer), the CA1 and CA3 region of the hippocampus and
areas of the somatomotor cortex (Figure 4B-D). Rats trea-
ted with Dox until P0 and P10 only showed gene activa-
tion in the olfactory bulb, the CA3 region and in few cells
of the cortex (Figure 4E-J). Previously, a similar weak
induction has also been observed in CaMKIIa-tTA mice
that were raised with Dox until P0 [26] or P21 [31]. Failure
to reach full expression has either been attributed to a Dox
clearance problem or to specific epigenetic modifications
of the Ptet-promoter sequences in CaMKIIa-positive neu-
rons during the suppression period [26,32,33].
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Figure 3 Doxycycline-mediated gene regulation in double transgenic CaMKIIa-tTA/EGFP-Ptetbi-Luc rats. (A-F) Doxycycline-controlled
EGFP expression in double transgenic CaMKIIa-tTA/EGFP-Ptetbi-luc rats was visualized by immunohistochemistry on sagittal sections using an
antibody against EGFP. (A-C) In the absence of Dox, strong but mosaic EGFP expression is found in the cortex and hippocampus (HC). (D-F) In
adult rats, EGFP expression could be completely inhibited by chronic Dox treatment (1 mg/mL drinking water) from conception until analyses.
(G-I) Dual-label fluorescent immunohistochemistry of brain slices with the neuronal marker NeuN and EGFP. (I) Co-localization of EGFP and NeuN
was frequently found in the CA1 region of the HC indicating Ptet-controlled reporter gene expression in the absence of Dox. (J) CaMKIIa-
promoter controlled tTA activity was directly visualized by EGFP fluorescence on sagittal brain sections of double transgenic CaMKIIa-tTA/EGFP-
Ptetbi-Luc rats in the HC. Strong expression is mainly found in neurons of the CA1 and CA3 region. (K,L) Level of luciferase activity in different
brain regions in the absence (-Dox, black) and presence of Dox (+Dox, 1 mg/mL, lightly shaded). The measured double transgenic animals were
obtained by crossing the CaMKIIa-tTA line 4.5 to the EGFP-Ptetbi-luc 66.1 reporter line. (K) Animals were treated with Dox from conception
throughout life until the day of analyses at the age of two months (+Dox, n = 5). Untreated control animals were measured at the same age
(-Dox, n = 8). In Dox-treated CaMKIIa-tTA/EGFP-Ptetbi-luc rats, virtually no luciferase activity could be detected, while strong luciferase activity
was found in all forebrain-specific regions (cortex, HC, olfactory bulb) of untreated rats (-Dox), leading to a highly significant difference between
Dox-treated and untreated rats (***P ≤ 0.001). (L) To assess whether reporter gene expression could be suppressed with Dox in adult rats (+Dox
adult), double transgenic animals, which had previously not received Dox, were treated with Dox for a period of three weeks during adulthood
(-Dox, n = 10, +Dox adult, n = 6). Administration of Dox during adulthood suppressed luciferase activity, leading to a significant difference
compared to untreated rats (***P ≤ 0.001). All data are presented as mean values + standard error of the mean. Logarithmic data transformation
was performed prior to statistical analysis. Stars represent P-values obtained by unpaired t-test. ***P ≤ 0.001. Light units are normalized to the
protein content of the lysates. Scale bar: 100 μm. Dox: doxycycline hydrochloride; EGFP: enhanced green fluorescent protein; HC: hippocampus.
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Figure 4 Activation of reporter gene expression after doxycycline withdrawal. Double transgenic CaMKIIa-tTA/EGFP-Ptetbi-Luc rats (4.5 ×
66.1) were treated with Dox during development until E18, P0 and P10, respectively (10 μg/mL). After 60 days of Dox withdrawal (±Dox),
reporter gene expression was analyzed by luciferase measurements of brain regions (A) and EGFP IHC (B-J). (A) A highly significant difference in
luciferase activity was found between the different groups (olfactory bulb: F (4,22) = 143, P < 0.001; cortex: F (4,22) = 79.4, P < 0.001;
hippocampus: F (4,22) = 125, P < 0.001; cerebellum: F (4,22) = 31.5, P < 0.001). In forebrain regions (olfactory bulb, cortex, hippocampus), strong
luciferase expression was induced by Dox withdrawal at E18, P0 and P10 (±Dox) compared with Dox-treated animals (+Dox). However, in rats
which had received Dox until birth (P0) or until P10, luciferase expression did not reach the level of untreated animals (-Dox). This suggests that
prolonged Dox treatment during development, in particular after birth, impairs activation of Ptet-controlled gene expression after Dox
withdrawal. Data are presented as mean + standard error of the mean. Logarithmic data transformation was performed prior to statistical
analysis. Characters (*, +, #) represent P-values obtained by one-way analysis of variance followed by Bonferroni post hoc analysis. * represents
significance levels versus +Dox (***P ≤ 0.001); + versus P10 (+P ≤ 0.05; +++P ≤ 0.001) and # versus P0 (#P ≤ 0.05; ##P ≤ 0.01; ###P ≤ 0.001). Light
units are normalized to the protein content of the lysates. (B-J) IHC confirms and extends the findings of the luciferase assays. Again, Dox-
treated rats which had received Dox only until E18 (B-D) showed a strong forebrain-specific reporter protein expression pattern which was
comparable to untreated rats (-Dox, Figure 3A-C) whereas the level of expression in all forebrain regions was significantly reduced when Dox
was given until P0 (E-G) or P10 (H-J). Dox: doxycycline hydrochloride; E: embryonic day; IHC: immunohistochemistry; P: postnatal day.
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In summary, we demonstrate strong, forebrain-specific
reporter gene expression in transgenic rats that can be
suppressed with Dox at any desired time. The bidirec-
tional expression module provides a useful tool for the
co-regulated expression of two genes at the same time.
However, prolonged Dox treatment restricts the ability to
reactivate Ptet-controlled gene expression in principle
forebrain neurons.
Inducible gene expression in rats using the Cre/loxP
system
The CreERT2/loxP system has been widely used for tis-
sue-specific and inducible gene ablations. Apart from this
application, the CreERT2/loxP system can also be used
as an alternative to the Tet system for conditional gene
overexpression [34,35]. While it does not allow for reversi-
ble activation of target genes, it allows for irreversible
Cre-mediated deletion or activation of loxP-flanked DNA
sequences. We explored this alternative inducible expres-
sion system in rats and compared it with the Tet system.
For this purpose, rat CaMKIIa-CreERT2 lines were gener-
ated and inducible recombination was functionally
assessed using a newly generated Cre reporter line.
Generation of CaMKIIa-CreERT2 rat lines
Again, the same mouse CaMKIIa promoter fragment was
chosen for tissue-specific control of CreERT2 recombinase
expression in forebrain neurons [5,36] (Figure 1B). Using
pronuclear DNA injections, we were able to generate 14
transgenic CaMKIIa-CreERT2 founders. Offspring from
all lines were initially analysed for Cre expression via IHC
using a Cre antibody [37], but only eight lines showed
notable Cre recombinase expression in the forebrain. We
selected four CaMKIIa-CreERT2 lines (327, 396, 404 and
408) which recapitulated the forebrain-specific CaMKIIa
expression pattern [38] most adequately with abundant
Cre-staining in most parts of the forebrain (Additional file
1), including the olfactory bulb, cortex and hippocampus.
Similar to the CaMKIIa-tTA lines described above, the
hippocampal dentate gyrus was largely devoid of trans-
genic expression. Sparse expression was also found in the
striatum and thalamus.
Generation of Cre reporter rats
We generated a rat Cre reporter line pCAG-loxP.LacZ.
loxP-EGFP (CAG-loxP.EGFP) to functionally characterize
Cre-mediated recombination (Figure 1B). The establish-
ment of a broadly applicable Cre reporter line critically
depends on the widespread expression of its reporter
genes, which ideally should not be limited to certain cell
types or be influenced by position-effect variegation.
Therefore, the chicken b-actin (CAG) promoter, which
has been shown to confer rather ubiquitous activity in
rodents in nearly all tissues [39-41], was used for the
design of the reporter construct. CAG promoter sequences
were placed upstream of a loxP-flanked (floxed) STOP
cassette containing a nuclear localized synthetic lacZ gene
and a bovine growth polyadenylation (polyA) signal to
ensure transcriptional termination. This lacZ/STOP cas-
sette was followed by EGFP as a second reporter gene.
Under baseline conditions, that is without Cre-mediated
recombination, the CAG promoter drives only b-galactosi-
dase (b-gal) but not EGFP expression. Upon Cre-mediated
recombination, the lacZ/STOP cassette is deleted, which
activates CAG-promoter controlled expression of EGFP.
To create transgenic rat Cre reporter lines, the CAG-
loxP.EGFP construct was microinjected in fertilized SD
oocytes, resulting in 12 Cre reporter founder rats. All
founders were first assayed for baseline, non-recombined
b-gal activity by X-Gal staining of primary fibroblast
cultures derived from ear biopsies (data not shown).
The primary fibroblast cultures of four founder animals
showed a strong nuclear X-Gal staining and those were
selected for further in vivo characterization.
Tissue slices and whole organs of single transgenic
CAG-loxP.EGFP rats were analysed by X-Gal staining.
Line 13 showed the most abundant b-gal signal of all
analysed lines (Additional file 2). Here, X-Gal staining
was detected in all organs analysed, with strong and
broad expression in fibroblasts, lung, kidneys, muscle,
heart, spleen, pancreas, stomach and gut. Only in the
liver was mosaic expression found.
Finally, we analysed CAG promoter activity in the
brain. Brain sections of transgenic CAG-loxP.EGFP off-
spring of the four b-gal-positive CAG-loxP.EGFP Cre
reporter lines were examined for b-gal expression using
X-Gal staining and IHC. Again, X-Gal staining of line
13 showed the strongest and broadest signal in the
brain (Figure 5A). Dual-label fluorescent IHC with anti-
bodies against b-gal and NeuN (Figure 5B,C) demon-
strated that most NeuN-positive neurons in the brain
also stained positive for b-gal (CA1: 93.4% ± 2.1%; cor-
tex 91.8% ± 4.7%; n = 3). By contrast, EGFP expression
could not be detected, which proves that the polyA sig-
nal downstream of the lacZ gene reliably functions as a
transcriptional STOP fragment, leading to tight regula-
tion of recombination-dependent EGFP expression. Our
results in rats demonstrate the broad applicability of the
CAG-loxP.EGFP line 13 for functional characterization
of newly generated tissue-specific rat Cre lines.
Analysis of Cre-mediated gene expression in double
transgenic CaMKIIa-CreERT2/CAG-loxP.EGFP rats
To functionally examine the spatial and temporal pattern
of CreERT2 recombinatorial activity, we crossed rats of
the four CaMKIIa-CreERT2 lines (327, 396, 408 and 404)
to our Cre reporter line CAG-loxP.EGFP to generate
bitransgenic CaMKIIa-CreERT2/CAG-loxP.EGFP rats.
At the age of 10 weeks, double transgenic rats were
intraperitoneally injected with tamoxifen (40 mg/kg)
alternately once or twice per day, resulting in a total of
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seven tamoxifen injections over five consecutive days. Ten
days after the last tamoxifen injection, animals were
analysed with IHC for EGFP to assess forebrain-specific
recombination (Figure 6). Of the four different transgenic
Cre lines, CaMKIIa-CreERT2 line 327 showed the most
efficient forebrain-specific recombination, that is, EGFP
expression, in the hippocampus and in the cortex (Figures
6A and 7E,H), whereas only scattered recombination was
found in the striatum and thalamus (Figure 7B). Outside
the forebrain, EGFP-positive cells were absent (Figure 7B).
This forebrain-specific recombination pattern concurs
with the recombination pattern found in CaMKIIa-
CreERT2 mice, where inducible Cre activity was primarily
found in the hippocampus and cortex and only low levels
of CreERT2 expression were identified in the striatum and
thalamus [42]. Importantly, the recombination pattern
(EGFP-positive) closely mirrored Cre expression (Figure
7A,B,D,E,G,H), demonstrating the excellent functionality
of the reporter line to detect Cre-mediated recombination
in the brain. We assume that the transgenic Cre reporter
rat described herein harbours multiple, randomly inte-
grated DNA fragments and might therefore represent an
easily accessible genomic locus, ideally suited for a broad
and sensitive detection of Cre-mediated recombination.
Next, we evaluated background recombination without
tamoxifen treatment (Figure 7C,F,I). Sparse recombined
EGFP-positive cells could be identified in various forebrain
regions, for example, in the cortical somatomotor area, the
postsubiculum and the piriform area. Such tamoxifen-
independent recombinase activity has also been described
for inducible CreERT transgenic mouse lines [43-45] and
is caused by the incomplete trapping of the Cre fusion
Figure 5 b-galactosidase expression in the brain of the CAG-loxP.EGFP Cre reporter line 13. (A) X-Gal staining of sagittal brain sections
demonstrates widespread b-galactosidase expression throughout the brain. (B,C) Neuronal b-galactosidase expression is demonstrated by co-
localization of the neuronal marker NeuN and nuclear localized b-galactosidase in the cortex (B) and CA1 region of the hippocampus (C). Scale
bar: 50 μm.
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protein in the cytosol in the absence of tamoxifen. Low
Cre activity in absence of the ligand was also found in
CaMK-CreERT2 mouse lines [42]. Interestingly, back-
ground recombination was not observed in CAG-loxP.
EGFP rats mated with less active CreERT2 driver lines,
thereby confirming the observation that the ligand-inde-
pendent activity of inducible Cre lines correlates with its
intracellular concentration [46].
To assess cell-type-specific neuronal recombination
after tamoxifen induction, double transgenic CaMKIIa-
CreERT2/CAG-loxP.EGFP rats were analysed with dual-
label fluorescent IHC using antibodies against EGFP and
NeuN (Figure 7J-O). Confocal microscopy of hippocam-
pal regions revealed 55.6% (±14.2%, n = 4) recombined
EGFP-positive/NeuN-positive neurons in CA1; 50.7%
(±4.5%, n = 3) in CA3; 52.7% (±11%, n = 3) in the hilus;
and 47.4% (±22.7%, n = 3) in cortical neurons.
In combination with the Cre reporter line CAG-loxP.
EGFP, we demonstrate effective temporal regulation of
Cre activity by tamoxifen treatment in the newly devel-
oped rat line CaMKIIa-CreERT2. In the absence of
tamoxifen, only minor recombination occurs, whereas
the application of tamoxifen results in widespread recom-
bination within forebrain neurons of the hippocampus
and cortex. In total, we were able to target about 50% of
NeuN-positive neurons in the aforementioned regions.
Similar to the Tet system, we assume that position-effect
variegations in the transgenic loci are responsible for the
overall variable expression [29,30]. We can exclude insuf-
ficient tamoxifen induction as the reason for this mosaic
expression pattern, because doubling the injection time
and thus tamoxifen dose did not lead to a higher recom-
bination rate. Both the CaMKIIa-tTA and CaMKIIa-
CreERT2 lines only sparsely mediate expression in the
Figure 6 CaMKIIa-CreERT2-mediated recombination in the rat brain. Functional recombination using different CaMKIIa-CreERT2 founder
lines was assessed with tamoxifen-induced double transgenic CaMKIIa-CreERT2/CAG-loxP.EGFP rats. Double transgenic rats were injected with
tamoxifen for five consecutive days. Ten days after the last injection, brain sections were prepared and analyzed by EGFP immunohistochemistry.
EGFP expression, which indicates Cre-mediated recombination, is restricted to forebrain structures. Recombination efficiency is dependent on the
Cre driver lines used. (A) CaMKIIa-CreERT2 line 327, (B) line 396, (C) line 408 and (D) line 404. EGFP: enhanced green fluorescent protein.
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dentate gyrus or in the striatum. This common pheno-
type is indicative that the used mouse CaMKIIa promo-
ter fragment lacks regulatory sequences needed for
expression specifically in this region in transgenic rats.
To date, only a limited number of Cre-expressing rat
lines have been published [47,48]. Tissue specificity and
temporal control of recombination was obtained by local
injections of Cre-expressing adenoviruses [49,50]. How-
ever, an increasing demand for tissue-specific Cre-
expressing rat lines can be anticipated in the near future,
as the first successful gene targeting in rat embryonic
stem cells was recently published [51] and several other
tools for the targeted modification of the rat genome,
such as zinc finger nucleases [11,12] or transcription acti-
vator-like effectors [52], are emerging. Thus, there is little
doubt that conditional alleles of target genes will also
become available in the rat. Another attractive applica-
tion is the injection of Cre-dependent viruses to achieve
optogenetic control of genetically defined cell types in
rats [48]. Moreover, as depicted here with the newly
developed Cre reporter line, the Cre/loxP technology can
be employed for the tissue-specific overexpression of
Figure 7 Tamoxifen-inducible recombination in double transgenic CaMKIIa-CreERT2/CAG-loxP.EGFP rats. Brain slices were immunostained
for (A,D,G) Cre recombinase or (B,C,E,F,H,I) EGFP expression. Tamoxifen (+Tx)-induced EGFP (B,E,H) expression mirrors Cre expression (A,D,G), whereas
uninduced animals (-Tx) only show low background recombination (C,F,I). (J-O) Brain slices of tamoxifen-induced CaMKIIa-CreERT2/CAG-loxP.EGFP rats
were double-stained for NeuN and EGFP. Co-localization of EGFP and NeuN demonstrated successful Cre-mediated recombination in neurons of the
cortex (L) and the CA1 region of the hippocampus (O). Scale bars: J-l 100 μm, M-O 50 μm. EGFP: enhanced green fluorescent protein.
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transgenes or alternatively for the knockdown of endo-
genous gene activities using polymerase II controlled
small hairpin RNAs [53,54]. The presented Cre reporter
line CAG-loxP.EGFP should provide a versatile tool for
the characterization of newly developed Cre rat lines in
both neural and non-neural tissues.
Conclusions
The laboratory rat was the earliest mammalian species
domesticated for scientific research and has been used as
such for over 150 years [6]. Although constitutive overex-
pression of genes in transgenic rats has been successfully
applied to generate relevant models for gene-related dis-
eases [55-57], only limited attempts have been made in
the past to establish transgenic rat models with inducible
and tissue-specific gene expression and no one has suc-
cessfully addressed the brain [58]. In transgenic mice, the
development of conditional strategies to control gene
expression in a spatial and temporal manner has been
crucial for modelling human diseases and deciphering
tissue-specific gene functions [1]. With new emerging
technologies, such as the presented forebrain-specific Cre
or tTA driver lines, techniques in transgenic rats will
close the gap with current mouse technologies. Such rat-
based disease models will complement existing mouse
models and the comparison of both will enable a better
differentiation between rodent-specific and general mam-
malian phenotypes [59,60].
Our experiences with both inducible systems suggest
complementary applications. The Tet system should be
applied for the overexpression of transgenes only during
embryonic development or until a defined time point
during adolescence, which then can be easily turned off
by feeding Dox. By contrast, with the CreERT2-based
system, a previously inactive expression module is effi-
ciently activated any time after birth.
Methods
Generation of transgenic rats
EGFP-Ptetbi-luc, CaMKIIa-tTA and CaMKIIa-CreERT2
transgenic lines
The generation of the EGFP-Ptetbi-luc tet-inducible
reporter line has been described previously [22]. For the
generation of forebrain-specific tTA and Cre-expressing
rats, a similar strategy was applied as published by May-
ford et al. [16]. In brief, the EcoRI-BamHI fragment cod-
ing for tTA2s (from pUHT61-1 [61]) and the EcoRI
CreERT2 fragment (derived from pCre-ERT2 [5]), respec-
tively, were placed downstream of the 8.5 kb CaMKIIa
promoter sequence (pMM403). Previously, the cDNAs
had been flanked by artificial introns at the 5’ and 3’ end
(from pNN265 [62]). A SV40 polyA sequence served as
the transcriptional termination signal. The CaMKIIa pro-
moter expression cassettes were separated from the vector
by digestion with SfiI, purified by DNA extraction from
agarose gel and microinjected at a concentration of 2 ng/
μL into fertilized SD eggs (Charles River, Sulzfeld, Ger-
many using procedures previously described [63]. All
experimental procedures were approved by the Animal
Welfare Committee (Regierungspräsidium Karlsruhe) and
carried out in accordance with the local Animal Welfare
Act and the European Communities Council Directive of
24 November 1986 (86/609/EEC).
pCAG-loxP.EGFP Cre reporter line
For monitoring Cre activity in transgenic rats, we
designed the expression vector pCAG-loxP-lacZ-loxP.
IRES-EGFP, a double-reporter construct, in which the
ubiquitous cytomegalovirus enhancer/CAG promoter
controls the expression of the lacZ gene before and
EGFP after Cre-mediated recombination. The construct
was assembled using the CAG promoter of the plasmid
pCAb, which was cloned upstream of the nuclear loca-
lized nlacZ gene from pMODlacZ (Invivogen, Toulouse,
France) and a bovine growth hormone polyA signal, the
latter being flanked by loxP sites. The expression cassette
is followed by a multiple cloning site to insert a gene of
interest, an internal ribosome entry site (IRES) sequence
from the encephalomyocarditis virus (derived from plas-
mid ETL[64]) and the EGFP open reading frame (Clon-
tech, Saint-Germain-en-Laye, France), followed by a
SV40 polyA sequence. For the generation of transgenic
rats harbouring the Cre double-reporter construct, a
PmeI-NotI fragment was released from the pCAG-loxP-
lacZ-loxP.IRES-EGFP vector and microinjected at a con-
centration of 2 ng/μL into fertilized SD rat eggs. Founder
rats and their offspring were analysed by Southern blot-
ting and polymerase chain reaction of tail DNA using pri-
mers for Cre, stTA [65], synlacZ (synlacZ_for: 5’-GC
TCAGGTCTCTCAATGGAG-3’, syn lacZ_rev 5’-CCAG
ACATCCTCCACATGTC-3’) and EGFP (eGFP_for 5’-
TTCAAGGACGACGGCAACTACAAG-3’, eGFP_rev 5’-
CGGCGGCGGTCACGAACTCC-3’). DNA was prepared
using the DNEasy Blood & Tissue Kit (QIAGEN, Hilden,
Germany).
Luciferase imaging in vivo
Double transgenic CaMKIIa-tTA/EGFP-Ptetbi-luc rats
were injected intraperitoneally with an aqueous solution
of D-luciferin (150 mg D-luciferin per kilogram of body
weight) and immediately placed into a light-tight cham-
ber. Subsequently, bioluminescent imaging was per-
formed following published procedures [24,25]. The
emitted light was detected with the IVIS imaging system
100 (Xenogen Corporation, Alameda, California, USA)
and analysis was performed using the LivingImage soft-
ware (version 2.50, Xenogen Corporation).
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Determination of luciferase activity in rat tissues
Tissue samples were homogenized in passive lysis buffer
(Promega, Mannheim, Germany) using the mixer-mill
Tissue Lyser for 20 seconds at 30 Hz with 3 mm tungsten
carbide beads. The homogenate was centrifuged for 5
minutes at 14,000 rpm at 4°C. The supernatants were
assayed in 10 mL samples for luciferase activity for 1 sec-
ond using the Luciferase Reporter Assay system (Promega)
according to the manufacturer’s instructions, in combina-
tion with Wallac Victor 2 multilabel counter (PerkinElmer,
Rodgau, Germany). An aliquot of the lysates was used to
determine the protein concentration by means of an
improved Bradford assay (BioRad, Munich, Germany).
Luciferase activities were normalized to micrograms
protein (RLU/μg).
Animal treatment (tamoxifen and doxycycline
hydrochloride
Dox was dissolved at a concentration of 1 mg/mL (+Dox
experiments) and 10 μg/mL (±Dox experiments) in tap
water supplemented with 5% sucrose and supplied to the
animals ad libitum. Tamoxifen (Sigma-Aldrich, Munich,
Germany, T5648) was dissolved in a pH neutral medium-
chain triglyceride (Neutralöl, Euro OTC Pharma, Bönen,
Germany) at a final concentration of 20 mg/mL. Two- to
three-month-old rats were injected intraperitoneally with
40 mg/kg body weight of tamoxifen alternating once or
twice per day for five consecutive days (starting with a
single injection on day 1). Experimental animals for
immunohistochemistry and Cre reporter analysis were
analysed 10 days after the last injection.
Immunohistochemistry and b-galactosidase staining
b-gal activity in transgenic rats was characterized by
X-Gal staining and IHC. Dissected brains were postfixed
with 4% paraformaldehyde at 4°C for 24 to 48 hours.
Brain sections (50 μm) were prepared using a vibratome
(Leica, Wetzlar, Germany). Floating sections were pro-
cessed for IHC using the VECTASTAIN ABC system
(Vector Laboratories, Burlingame, California, USA) and
diaminobenzidine (Sigma-Aldrich) in combination with
polyclonal rabbit anti-Cre (a generous gift from G.
Schütz, DKFZ, 1:3000) and polyclonal rabbit anti-GFP
(Invitrogen, Darmstadt, Germany 1:1000) antibodies.
Double fluorescence IHC was performed to visualize
b-gal and GFP expression in NeuN-positive neurons using
the primary antibodies chicken anti-b-gal (Abcam, Cam-
bridge, UK, 1:10,000), mouse monoclonal anti-NeuN
(Millipore, Schwalbach, Germany 1:4,000) and polyclonal
rabbit anti-GFP (Invitrogen, 1:1,000). Brain sections were
permeabilized with Triton X-100 (0.1%) for 30 minutes in
1 × PBS at 4°C, washed with 1 × PBS (three times) and
blocked with 10% donkey serum in 1 × PBS for 1 hour.
The primary antibodies were added to the blocking
solution and incubated at 4°C overnight on an orbital
shaker. Next day, following three washings with PBS, the
sections were incubated in blocking solution containing
the secondary antibodies for 1 hour at room temperature.
After final washes with 1 × PBS, sections were mounted in
Dako fluorescence mounting medium. Secondary antibo-
dies were AF488 donkey a-mouse (Invitrogen, 1:200) and
Cy3 donkey a-chicken (1:1,000). Sagittal vibratome
sections were examined using confocal laser-scanning
microscopes (Nikon C1Si-CLEM, Nikon Imaging Center,
BioQuant, Heidelberg, Germany and Leica TCS SP5, Cen-
tral Institute of Mental Health, Mannheim, Germany).
For b-gal staining, similar brain sections were incubated
with X-Gal staining solution (5 mM EGTA, 2 mM MgCl2,
0.01% C24H39O4Na, 0.02% NP-40, 10 mM K3(Fe(CN)6), 10
mM K4(Fe(CN)6) and 0.5 mg/mL X-Gal in 1 × PBS) at 37°
C for several hours. Finally, the stained slices were coun-
terstained with nuclear fast red (Sigma) and mounted with
Eukitt (O. Kindler, Freiburg, Germany).
Ear fibroblast culture and transfection
Ear fibroblast cultures were prepared from ear biopsies of
founder animals using a protocol previously described
[66]. Depending on the transgene, the cells were directly
examined either by X-Gal staining or transfected with tTA
expression plasmids using lipofectamine-2000 (Invitrogen)
according to the manufacturer’s protocol.
Statistical analysis
Statistical analyses of luciferase data were performed using
either t-test or univariate analysis of variance (ANOVA),
followed by Bonferroni post hoc analysis. Respective F-and
P-values were calculated using GraphPad Prism 5.0. All
data are presented as mean ± standard error of the mean
(SEM). A P-value ≤ 0.05 was considered statistically signif-
icant. Sagittal slices of adult pCAG-loxP.EGFP, CaMKIIa-
tTA/EGFP-Ptetbi-luc and CaMKIIa-CreERT2/CAG-loxP.
EGFP rats were processed with dual-label fluorescent IHC
detecting EGFP and NeuN. Images were acquired using a
confocal laser-scanning microscope. The ratio of GFP-
positive/NeuN-positive neurons to all NeuN-positive
neurons was calculated separately for cortex and hippo-
campal regions (CA1, CA3 and hilus). Mean and SEM
were calculated from at least three rats per group.
Commitment to distribute transgenic rat lines
All transgenic rat lines generated in this project will be
made available upon request to scientists at academic
institutions for non-commercial research or deposited into
a repository/stock centre, making them available to the
broader research community. We will process requests in
an appropriate timely fashion and in the order of request
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received, provided the recipient will bear all costs for the
shipment and sign our institutional Material Transfer
Agreement. For scientists requesting rats harbouring
components of the Tet system, the Notice and Acknowl-
edgement Agreement (N&A) of ‘TET Systems’ available at
http://www.tetsystems.com/ip-licensing/licensing/not-for-
profit-research needs to be completed before these rats
can be transferred to recipients.
Additional material
Additional file 1: CreERT2 protein expression in the brain of
transgenic CaMKIIa-CreERT2 rats. CaMKIIa-CreERT2 rats were injected
twice within 12 hours with tamoxifen for nuclear localization of the Cre
recombinase. Three hours after the second injection, animals were
prepared for analysis. Brain sections were immunostained using a Cre
antibody. The most prominent Cre immunoreactivity was found in
hippocampal pyramidal neurons (B,C,E,G) and in cortical structures.
CaMKIIa-CreERT2 line 327 (A,B); line 396 (C,D); line 408 (E,F) and line 404
(G,H).
Additional file 2: Constitutive b-galactosidase expression in
transgenic pCAG-loxP.EGFP Cre reporter rats. Macroscopic
appearance of X-Gal-stained tissues revealed strong b-galactosidase
expression in the lung, kidney, muscle, heart, spleen and gastrointestinal
tract including appendix and pancreas.
Abbreviations
ANOVA: analysis of variance; β-gal: β-galactosidase; CAG: chicken β-actin;
Dox: doxycycline hydrochloride; E: embryonic day; EGFP: enhanced green
fluorescent protein; GFP: green fluorescent protein; IHC:
immunohistochemistry; P: postnatal day; PBS: phosphate-buffered saline;
SEM: standard error of the mean; RLU: relative light units; tet: tetracycline;
tTA: tetracycline-dependent transactivator.
Acknowledgements
We thank the animal care team of the Central Institute of Mental Health for
assistance in animal handling. We also thank Günther Schütz for providing
the Cre antibody and Pierre Chambon for the CreERT2 plasmid. This work
was funded by the following grants: EU HEALTH-F2-2007-201714 DEVANX,
the German Ministry of Education and Research (BMBF, 01GQ1003B) and
BMBF NGFN-Plus grant (01GS0851) to DB.
Author details
1Department of Molecular Biology, Central Institute of Mental Health and
Heidelberg University, Medical Faculty Mannheim, J5, 68159 Mannheim,
Germany. 2Department of Addictive Behavior and Addiction Medicine,
Central Institute of Mental Health, Heidelberg University, J5, 68159
Mannheim, Germany. 3German Cancer Research Center (DKFZ), Molecular
Immunology, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany.
4Zentrum für Molekulare Biologie Heidelberg, Im Neuenheimer Feld 282,
69120 Heidelberg, Germany.
Authors’ contributions
KS conceived the study, generated transgenic DNA constructs, collected and
analysed experimental data and drafted the manuscript. TW participated in
the design of the study, carried out the statistical analysis and drafted the
manuscript. AF performed DNA microinjections and genotyping of the
transgenic animals. LW functionally analysed the expression pattern of the
CaMKIIα-tTA and CaMKIIα-CreERT2 founder lines by X-Gal stainings, luciferase
measurements and IHC. BP helped in the cloning of transgenic constructs.
DD performed in vivo luciferase imaging experiments. HB and DB conceived
the study and helped to draft the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 June 2012 Accepted: 3 September 2012
Published: 3 September 2012
References
1. Lewandoski M: Conditional control of gene expression in the mouse. Nat
Rev Genet 2001, 2(10):743-755.
2. van der Weyden L, White JK, Adams DJ, Logan DW: The mouse genetics
toolkit: revealing function and mechanism. Genome Biol 2011, 12(6):224.
3. Sauer B, Henderson N: Site-specific DNA recombination in mammalian
cells by the Cre recombinase of bacteriophage P1. Proc Nat Acad Sci USA
1988, 85(14):5166-5170.
4. Gossen M, Bujard H: Tight control of gene expression in mammalian cells
by tetracycline-responsive promoters. Proc Nat Acad Sci USA 1992,
89(12):5547-5551.
5. Feil R, Wagner J, Metzger D, Chambon P: Regulation of Cre recombinase
activity by mutated estrogen receptor ligand-binding domains. Biochem
Biophys Res Commun 1997, 237(3):752-757.
6. Jacob HJ: Functional genomics and rat models. Genome Res 1999,
9(11):1013-1016.
7. Abbott A: Laboratory animals: the Renaissance rat. Nature 2004,
428(6982):464-466.
8. Aitman TJ, Critser JK, Cuppen E, Dominiczak A, Fernandez-Suarez XM, Flint J,
Gauguier D, Geurts AM, Gould M, Harris PC, Holmdahl R, Hubner N,
Izsvák Z, Jacob HJ, Kuramoto T, Kwitek AE, Marrone A, Mashimo T,
Moreno C, Mullins J, Mullins L, Olsson T, Pravenec M, Riley L, Saar K,
Serikawa T, Shull JD, Szpirer C, Twigger SN, Voigt B, Worley K: Progress and
prospects in rat genetics: a community view. Nat Genet 2008,
40(5):516-522.
9. Costantini LC, Bakowska JC, Breakefield XO, Isacson O: Gene therapy in the
CNS. Gene Ther 2000, 7(2):93-109.
10. van Boxtel R, Cuppen E: Rat traps: filling the toolbox for manipulating the
rat genome. Genome Biol 2010, 11(9):217.
11. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, Jenkins SS,
Wood A, Cui X, Meng X, Vincent A, Lam S, Michalkiewicz M, Schilling R,
Foeckler J, Kalloway S, Weiler H, Ménoret S, Anegon I, Davis GD, Zhang L,
Rebar EJ, Gregory PD, Urnov FD, Jacob HJ, Buelow R: Knockout rats via
embryo microinjection of zinc-finger nucleases. Science 2009,
325(5939):433.
12. Cui X, Ji D, Fisher DA, Wu Y, Briner DM, Weinstein EJ: Targeted integration
in rat and mouse embryos with zinc-finger nucleases. Nature Biotechnol
2011, 29(1):64-67.
13. Zhang F, et al: Efficient construction of sequence-specific TAL effectors
for modulating mammalian transcription. Nature Biotechnol 2011,
29(2):149-153.
14. Buehr M, Meek S, Blair K, Yang J, Ure J, Silva J, McLay R, Hall J, Ying QL,
Smith A: Capture of authentic embryonic stem cells from rat blastocysts.
Cell 2008, 135(7):1287-1298.
15. Li P, Tong C, Mehrian-Shai R, Jia L, Wu N, Yan Y, Maxson RE, Schulze EN,
Song H, Hsieh CL, Pera MF, Ying QL: Germline competent embryonic
stem cells derived from rat blastocysts. Cell 2008, 135(7):1299-1310.
16. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER: Control
of memory formation through regulated expression of a CaMKII
transgene. Science 1996, 274(5293):1678-1683.
17. Schönig K, Bujard H, Gossen M: The power of reversibility regulating gene
activities via tetracycline-controlled transcription. Methods Enzymol 2010,
477:429-453.
18. Chen J, Kelz MB, Zeng G, Sakai N, Steffen C, Shockett PE, Picciotto MR,
Duman RS, Nestler EJ: Transgenic animals with inducible, targeted gene
expression in brain. Mol Pharmacol 1998, 54(3):495-503.
19. Tichelaar JW, Lu W, Whitsett JA: Conditional expression of fibroblast
growth factor-7 in the developing and mature lung. J Biol Chem 2000,
275(16):11858-11864.
20. Thomas MK, Devon ON, Lee JH, Peter A, Schlosser DA, Tenser MS,
Habener JF: Development of diabetes mellitus in aging transgenic mice
following suppression of pancreatic homeoprotein IDX-1. J Clin Invest
2001, 108(2):319-329.
Schönig et al. BMC Biology 2012, 10:77
http://www.biomedcentral.com/1741-7007/10/77
Page 14 of 16
21. Baron U, Freundlieb S, Gossen M, Bujard H: Co-regulation of two gene
activities by tetracycline via a bidirectional promoter. Nucleic Acids Res
1995, 23(17):3605-3606.
22. Schönig K, Kentner D, Gossen M, Baldinger T, Miao J, Welzel K, Vente A,
Bartsch D, Bujard H: Development of a BAC vector for integration-
independent and tight regulation of transgenes in rodents via the Tet
system. Transgenic Res 2011, 20(3):709-720.
23. Boross P, Breukel C, van Loo PF, van der Kaa J, Claassens JW, Bujard H,
Schönig K, Verbeek JS: Highly B lymphocyte-specific tamoxifen inducible
transgene expression of CreER T2 by using the LC-1 locus BAC vector.
Genesis 2009, 47(11):729-735.
24. Contag CH, Bachmann MH: Advances in in vivo bioluminescence imaging
of gene expression. Annu Rev Biomed Eng 2002, 4:235-260.
25. Hasan MT, Schonig K, Berger S, Graewe W, Bujard H: Long-term,
noninvasive imaging of regulated gene expression in living mice. Genesis
2001, 29(3):116-122.
26. Krestel HE, Shimshek DR, Jensen V, Nevian T, Kim J, Geng Y, Bast T, Depaulis A,
Schonig K, Schwenk F, Bujard H, Hvalby Ø, Sprengel R, Seeburg PH: A genetic
switch for epilepsy in adult mice. J Neurosci 2004, 24(46):10568-10578.
27. Lindeberg J, Mattsson R, Ebendal T: Timing the doxycycline yields
different patterns of genomic recombination in brain neurons with a
new inducible Cre transgene. J Neurosci Res 2002, 68(2):248-253.
28. Ghavami A, Stark KL, Jareb M, Ramboz S, Ségu L, Hen R: Differential
addressing of 5-HT1A and 5-HT1B receptors in epithelial cells and
neurons. J Cell Sci 1999, 112(Pt 6):967-976.
29. Dobie K, Mehtali M, McClenaghan M, Lathe R: Variegated gene expression
in mice. Trends Genet 1997, 13(4):127-130.
30. Robertson G, Garrick D, Wu W, Kearns M, Martin D, Whitelaw E: Position-
dependent variegation of globin transgene expression in mice. Proc Nat
Acad Sci USA 1995, 92(12):5371-5375.
31. Krestel HE, Mayford M, Seeburg PH, Sprengel R: A GFP-equipped
bidirectional expression module well suited for monitoring tetracycline-
regulated gene expression in mouse. Nucleic Acids Res 2001, 29(7):E39.
32. Bejar R, Yasuda R, Krugers H, Hood K, Mayford M: Transgenic calmodulin-
dependent protein kinase II activation: dose-dependent effects on
synaptic plasticity, learning, and memory. J Neurosci 2002,
22(13):5719-5726.
33. Zhu P, Aller MI, Baron U, Cambridge S, Bausen M, Herb J, Sawinski J,
Cetin A, Osten P, Nelson ML, Kügler S, Seeburg PH, Sprengel R, Hasan MT:
Silencing and un-silencing of tetracycline-controlled genes in neurons.
PloS One 2007, 2(6):e533.
34. Ryding AD, Sharp MG, Mullins JJ: Conditional transgenic technologies.
J Endocrinol 2001, 171(1):1-14.
35. Nagy A: Cre recombinase: the universal reagent for genome tailoring.
Genesis 2000, 26(2):99-109.
36. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D:
Temporally-controlled site-specific mutagenesis in the basal layer of the
epidermis: comparison of the recombinase activity of the tamoxifen-
inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 1999,
27(22):4324-4327.
37. Kellendonk C, Tronche F, Casanova E, Anlag K, Opherk C, Schütz G: Inducible
site-specific recombination in the brain. J Mol Biol 1999, 285(1):175-182.
38. Minichiello L, Korte M, Wolfer D, Kühn R, Unsicker K, Cestari V, Rossi-Arnaud C,
Lipp HP, Bonhoeffer T, Klein R: Essential role for TrkB receptors in
hippocampus-mediated learning. Neuron 1999, 24(2):401-414.
39. Murakami T, Kobayashi E: Color-engineered rats and luminescent LacZ
imaging: a new platform to visualize biological processes. J Biomed Opt
2005, 10(4):41204.
40. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y: ’Green mice’ as
a source of ubiquitous green cells. FEBS letters 1997, 407(3):313-319.
41. Hakamata Y, Tahara K, Uchida H, Sakuma Y, Nakamura M, Kume A,
Murakami T, Takahashi M, Takahashi R, Hirabayashi M, Ueda M, Miyoshi I,
Kasai N, Kobayashi E: Green fluorescent protein-transgenic rat: a tool for
organ transplantation research. Biochem Biophys Res Commun 2001,
286(4):779-785.
42. Erdmann G, Schutz G, Berger S: Inducible gene inactivation in neurons of
the adult mouse forebrain. BMC Neurosci 2007, 8:63.
43. Kemp R, Ireland H, Clayton E, Houghton C, Howard L, Winton DJ:
Elimination of background recombination: somatic induction of Cre by
combined transcriptional regulation and hormone binding affinity.
Nucleic Acids Rese 2004, 32(11):e92.
44. Hameyer D, Loonstra A, Eshkind L, Schmitt S, Antunes C, Groen A, Bindels E,
Jonkers J, Krimpenfort P, Meuwissen R, Rijswijk L, Bex A, Berns A,
Bockamp E: Toxicity of ligand-dependent Cre recombinases and
generation of a conditional Cre deleter mouse allowing mosaic
recombination in peripheral tissues. Physiol Genomics 2007, 31(1):32-41.
45. Liu Y, Suckale J, Masjkur J, Magro MG, Steffen A, Anastassiadis K,
Solimena M: Tamoxifen-independent recombination in the RIP-CreER
mouse. PloS One 2010, 5(10):e13533.
46. Buelow B, Scharenberg AM: Characterization of parameters required for
effective use of tamoxifen-regulated recombination. PloS One 2008, 3(9):
e3264.
47. Weber T, Schonig K, Tews B, Bartsch D: Inducible gene manipulations in
brain serotonergic neurons of transgenic rats. PloS One 2011, 6(11):
e28283.
48. Witten IB, et al: Recombinase-driver rat lines: tools, techniques, and
optogenetic application to dopamine-mediated reinforcement. Neuron
2011, 72(5):721-733.
49. Sato Y, Endo H, Ajiki T, Hakamata Y, Okada T, Murakami T, Kobayashi E:
Establishment of Cre/LoxP recombination system in transgenic rats.
Biochem Biophys Res Commun 2004, 319(4):1197-1202.
50. Ueda S, Fukamachi K, Matsuoka Y, Takasuka N, Takeshita F, Naito A, Iigo M,
Alexander DB, Moore MA, Saito I, Ochiya T, Tsuda H: Ductal origin of
pancreatic adenocarcinomas induced by conditional activation of a
human Ha-ras oncogene in rat pancreas. Carcinogenesis 2006,
27(12):2497-2510.
51. Tong C, Li P, Wu NL, Yan Y, Ying QL: Production of p53 gene knockout
rats by homologous recombination in embryonic stem cells. Nature 2010,
467(7312):211-213.
52. Tesson L, Usal C, Ménoret S, Leung E, Niles BJ, Remy S, Santiago Y,
Vincent AI, Meng X, Zhang L, Gregory PD, Anegon I, Cost GJ: Knockout rats
generated by embryo microinjection of TALENs. Nat Biotechnol 2011,
29(8):695-696.
53. Berger SM, Pesold B, Reber S, Schönig K, Berger AJ, Weidenfeld I, Miao J,
Berger MR, Gruss OJ, Bartsch D: Quantitative analysis of conditional gene
inactivation using rationally designed, tetracycline-controlled miRNAs.
Nucleic Acids Res 2010, 38(17):e168.
54. Dickins RA, McJunkin K, Hernando E, Premsrirut PK, Krizhanovsky V,
Burgess DJ, Kim SY, Cordon-Cardo C, Zender L, Hannon GJ, Lowe SW:
Tissue-specific and reversible RNA interference in transgenic mice. Nat
Genet 2007, 39(7):914-921.
55. Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats
harbouring the mouse Ren-2 gene. Nature 1990, 344(6266):541-544.
56. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD: Spontaneous
inflammatory disease in transgenic rats expressing HLA-B27 and human
beta 2m: an animal model of HLA-B27-associated human disorders. Cell
1990, 63(5):1099-1112.
57. Herrera VL, Makrides SC, Xie HX, Adari H, Krauss RM, Ryan US, Ruiz-Opazo N:
Spontaneous combined hyperlipidemia, coronary heart disease and
decreased survival in Dahl salt-sensitive hypertensive rats transgenic for
human cholesteryl ester transfer protein. Nat Med 1999, 5(12):1383-1389.
58. Konopka W, Duniec K, Klejman A, Wawrzyniak M, Owczarek D, Gawrys L,
Maleszewski M, Mallet J, Kaczmarek L: Tet system in the brain: transgenic
rats and lentiviral vectors approach. Genesis 2009, 47(4):274-280.
59. Gao X, Zhang P: Transgenic RNA interference in mice. Physiology
(Bethesda) 2007, 22:161-166.
60. Zhou H, Huang C, Yang M, Landel CP, Xia PY, Liu YJ, Xia XG: Developing
tTA transgenic rats for inducible and reversible gene expression. Int J Bio
Sci 2009, 5(2):171-181.
61. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W: Exploring
the sequence space for tetracycline-dependent transcriptional activators:
novel mutations yield expanded range and sensitivity. Proc Nat Acad Sci
USA 2000, 97(14):7963-7968.
62. Choi T, Huang M, Gorman C, Jaenisch R: A generic intron increases gene
expression in transgenic mice. Mol Cell Biol 1991, 11(6):3070-3074.
63. Hogan H, Beddington R, Constantini F, Lacy E: Manipulating the Mouse
Embryo: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor
Laboratory Press;, 2 1994.
64. Mombaerts P, Wang F, Dulac C, Chao SK, Nemes A, Mendelsohn M,
Edmondson J, Axel R: Visualizing an olfactory sensory map. Cell 1996,
87(4):675-686.
Schönig et al. BMC Biology 2012, 10:77
http://www.biomedcentral.com/1741-7007/10/77
Page 15 of 16
65. Schönig K, Schwenk F, Rajewsky K, Bujard H: Stringent doxycycline
dependent control of CRE recombinase in vivo. Nucleic Acids Res
30(23):e134.
66. Schönig K, Bujard H: Generating conditional mouse mutants via
tetracycline-controlled gene expression. Methods Mol Biol 2003,
209:69-104.
doi:10.1186/1741-7007-10-77
Cite this article as: Schönig et al.: Conditional gene expression systems
in the transgenic rat brain. BMC Biology 2012 10:77.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schönig et al. BMC Biology 2012, 10:77
http://www.biomedcentral.com/1741-7007/10/77
Page 16 of 16
